The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...
In patients with metastatic breast cancer (mBC) who progress after first-line treatment of CDK4/6 and aromatase inhibitors ...
In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, GI medical oncologist at Baptist Health Miami Cancer ...
A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...
The landscape of triple-negative breast cancer (TNBC) is shifting rapidly. What was once a landscape dominated by standard cytotoxic chemotherapy is now a complex map of immunotherapy, PARP inhibitors ...
A new drug application (NDA) and a biologics license application (BLA) have been resubmitted and accepted by the FDA for ...
The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the ...
During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal ...
QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...
Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing ...
A significant portion of the clinical management for ADCs involves addressing payload-dependent toxicities, with interstitial lung disease (ILD) being a notable safety concern and potentially serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results